CG Oncology, Inc. (CGON) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-08

Key Insights

CG Oncology filed an 8-K on May 8, 2026 announcing Q1 2026 financial results (quarter ended March 31, 2026), indicating the company is actively reporting financial performance to the market.
The filing references a press release (Exhibit 99.1) as the substantive disclosure mechanism, which is standard practice for earnings announcements but does not include detailed financial metrics in the 8-K itself.
The document is explicitly disclaimed from being 'filed' for purposes of Section 18 of the Exchange Act, limiting liability exposure and indicating this is a routine quarterly earnings disclosure rather than a material event filing.

Want the newest filings?

This analysis covers the filing from 2026-05-08. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-13

CG Oncology, Inc. has appointed Jim DeTore as the new Chief Financial Officer, who has served as the Interim Principal Financial and Accounting Officer since November 2025.
The employment agreement with the new CFO includes an initial annual base salary of $520,000, an annual target bonus of 45%, and equity awards valued at $5 million.
The agreement also provides severance benefits for certain terminations, including accelerated vesting of equity awards upon a change in control.

Filed: 2026-02-27

CG Oncology reported its financial results for the year and quarter ended December 31, 2025, indicating the company's performance during this period.
The company did not provide any forward-looking guidance or commentary on its business outlook in the press release.
No other material information or significant events were disclosed in this 8-K filing.

Filed: 2026-01-13

CG Oncology filed an amendment to increase the size of its at-the-market (ATM) equity offering program from $250 million to $550 million, allowing the company to raise additional capital to fund its operations and development activities.
The company previously sold $250 million in shares under the original ATM program, demonstrating investor demand and the company's ability to access the public markets for funding.
The expanded ATM program provides CG Oncology with greater financial flexibility to execute on its strategic priorities and advance its oncology pipeline as it seeks to capitalize on the growing cancer treatment market.

Filed: 2026-01-09

CG Oncology has announced an expedited timeline for the topline data readout of its Phase 3 PIVOT-006 clinical trial, which is evaluating its lead candidate cretostimogene grenadenorepvec in patients with intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). The topline data is now expected in the first half of 2026, earlier than previously anticipated.
The company has also reported encouraging topline results from two additional trials - BOND-003 Cohort P and CORE-008 Cohort A - which demonstrated promising efficacy, safety, and tolerability profiles for cretostimogene in patients with BCG-unresponsive papillary-only NMIBC and high-risk, BCG-naïve NMIBC with carcinoma in situ (CIS), respectively.
These positive clinical developments across CG Oncology's pipeline suggest the potential for cretostimogene to address significant unmet needs in the NMIBC treatment landscape, which could drive value for the company and its shareholders.

Other reports for CG Oncology, Inc.

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.